QIAGEN to open regional headquarters in Riyadh, Saudi Arabia, at the beginning of 2024 to support growing presence in the region QIAGEN signed Memor...
This investment opportunity offers a unique chance for individuals and institutions to actively participate in the growth and transformation of the healthc...
The European Patent office granted patent No. 3105587 titled 'Method of Qualifying of Cells' for a method of qualifying whether a cell population is a suit...
EMA assessed arpraziquantel under the EU-M4all procedure for high-priority medicines intended for use in countries outside the European Union Merck is c...
Set-up of first BioNTainer as high-tech manufacturing solution for mRNA medicines is a critical step in establishing a resilient vaccine ecosystem in Afr...
Parse Biosciences, a leading provider of easily accessible and scalable solutions for single-cell sequencing, announced today that the company has raised $...
Biolojic’s BD9 is a multibody that was computationally designed as a multi specific antibody targeting IL-13 / TSLP to treat inflammatory diseases....
The Healthcare+ Expo Taiwan, currently taking place at Nangang Exhibition Hall 1 from November 30 to December 3, 2023, is poised to redefine the landscape ...
ReWalk Robotics, Ltd. (Nasdaq: RWLK) ("ReWalk" or the "Company"), a leading provider of innovative technologies that enable mobility and wellness in r...
SciSparc’s novel SCI-210 therapy is not only a medication based on CBD; it is also a unique combination of cannabidiol (CBD) and SciSparc's proprieta...
Major Milestone Met in AI-Powered Fight Against Lung Cancer Global initiative gains significant ground in digitally identifying cancer risk before s...
Genomic medicine, also known as precision medicine, offers transformative opportunities to reshape health care and public health from a 'one size fits all'...
SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central...
Royalty Pharma to provide R&D funding support of up to $125 million for the development of olanzapine LAI (TEV-‘749), a long-acting subcutaneou...
© 2024 Biopharma Boardroom. All Rights Reserved.
